Bayer AG receives Investment Bank Analyst Rating Update
By Ross Kerber CAMBRIDGE, Mass. (Reuters) - Supply chain shortages cost Bayer AG up to 3% of lost sales in its crop protection business this year, CEO Werner Baumann said on...
FRANKFURT (Reuters) - Bayer (ETR:BAYGN)'s supervisory board has initiated a search for a successor to Chief Executive Werner Baumann, who has said he would not seek a renewal of...
China factory growth unexpectedly slumps German retail data surprises to the downside Markets await Fed interest rate decision Key EventsDespite European and Asian shares selling...
In January, US consumer prices charged higher as the Consumer Price Index (CPI) for All Urban Consumers (CPI-U) went up by 0.6%. Inflation now stands at 7.5%, the highest figure in...
Commodities have been getting significant attention in recent weeks, and possibly for good reason. The Federal Reserve, as well as many other central banks, is likely to keep...
Bayer AG is a German-based life science company. The Company's segments are Pharmaceuticals, Consumer Health, Crop Science. The Pharmaceuticals segment focuses on researching, developing and marketing prescription products and specialty therapeutics especially in the areas of cardiology, oncology, gynecology, hematology and ophthalmology, as well as radiopharmacology and others. The Company is focusing on their oncology platform for Targeted Alpha Therapies for treating prostate cancer. The Consumer Health segment develops, produces and markets nonprescription over-the-counter products in the dermatology, dietary supplement, analgesic, gastrointestinal, cold, allergy, sinus and flu, foot care and sun protection categories, among others. The Crop Science segment researches, develops and markets crop protection solutions and seeds.
|Average||20.82 (+80.10% Upside)|
|No. of Analysts||2|